

Product Name: Mitoxantrone HCI Revision Date: 09/13/2024

Product Data Sheet

Mitoxantrone HCI

Cat. No.:	B2114 reduction t	HO
CAS No.:	70476-82-3	NH HO
Formula:	C22H29CIN4O6·HCI	ОН
M.Wt:	517.4	
Synonyms:		
Target:		NH L
Pathway:		HN.
Storage:	Store at -20°C	E The second of
Solvent	& Solubility	Sol frame Parameter

In Vitro	Preparing Stock Solutions	Solvent Concentration	1mg	5mg	10mg
III VIIIO		1 mM	1.9327 mL	9.6637 mL	19.3274 mL
	EIO	5 mM	0.3865 mL	1.9327 mL	3.8655 mL
		10 mM	0.1933 mL	0.9664 mL	1.9327 mL

insoluble in EtOH; ≥51.53 mg/mL in DMSO; ≥2.97 mg/mL in H2O with ultrasonic

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary

Topoisomerase II inhibitor, anti-neoplastic drug

IC50 & Target

In Vitro

Cell Viability Assay	Contract of the second
Cell Line: not contract	DPSCs and HDFs
Preparation method:	The solubility of this compound in DMSO is > 18.2 mg/mL. General tips for
	obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes
	and/or shake it in the ultrasonic bath for a while. Stock solution can be stored
	below - 20 °C for several months.
Reacting conditions:	5, 20, 50, 100 and 150 nM
	1 Junior analytic app

1 | www.apexbt.com

	Applications:	Mitoxantrone HCI almost completely inhibited DPSCs and HDFs proliferation			
		without causing significant decrease in cell viability after 6 days. Mitoxantrone			
		HCI, at higher doses, i.e. 100 nM and 150 nM, significantly decreased DPSCs			
		and HDFs viability after 3 days. In addition, Mitoxantrone HCl at doses over 50			
	Burnown	nM significantly increased the activity of caspases 3/7 and the level of puma,			
	Etopos ma U	inducing DPSCs and HDFs apoptosis.			
	Animal experiment	alle and a second a			
	Animal models:	Mice bearing PAC120 and HID xenografts			
	Dosage form:	1 mg/kg; i.p.; once per 3 weeks			
	Applications:	In mice bearing PAC120 xenografts, Mitoxantrone HCI was well tolerated,			
		although it caused a weight loss of 10% or less. However, it did not inhibit tumor			
In Vivo		growth. In mice bearing HID xenografts, Mitoxantrone HCI transiently inhibited			
		tumor growth with the optimal effect 3 weeks after the start of treatment. After			
	-0	30 days, Mitoxantrone HCI no longer exhibited any inhibitory effect on tumor			
	Breumoun	growth.			
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may			
	Active Porto	slightly differ with the theoretical value. This is caused by an experimental			
		system error and it is normal.			

Product Citations

See more customer validations on www.apexbt.com.

References

[1]. Seifrtova M, Havelek R, Soukup T, Filipova A, Mokry J, Rezacova M. Mitoxantrone ability to induce premature senescence in human dental pulp stem cells and human dermal fibroblasts. J Physiol Pharmacol. 2013 Apr;64(2):255-66.

APERBIC

[2]. Oudard S, Legrier ME, Boyé K, Bras-Gonalves R, De Pinieux G, De Cremoux P, Poupon MF. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol. 2003 May;169(5):1729-34.



FOR RESEARCH PURPOSES ONLY. NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for **2** | www.apexbt.com

long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com





APE







